Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 1,324.00 1,318.00 1,318.60 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.0 6,221.0 93.9 14.1 66,430

GlaxoSmithKline PLC Sanofi/GSK agree up to 72m Canada COVID doses

22/09/2020 5:42pm

UK Regulatory (RNS & others)


Glaxosmithkline (LSE:GSK)
Historical Stock Chart


From Aug 2020 to Oct 2020

Click Here for more Glaxosmithkline Charts.

TIDMGSK

RNS Number : 7850Z

GlaxoSmithKline PLC

22 September 2020

Issued: 22(nd) September 2020, London, UK and Paris, France

Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine

-- Agreements relate to vaccine candidate using Sanofi's recombinant protein-based technology and GSK's pandemic adjuvant

-- Both companies are committed to making their COVID-19 vaccine affordable and available globally

Sanofi and GSK have today signed agreements with the Government of Canada for the supply of up to 72 million doses of an adjuvanted COVID-19 vaccine, beginning in 2021.

Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur, said:

"Today's announcement showcases our unwavering commitment to develop a COVID-19 vaccine that is available to everyone when it comes to market. To address a global health crisis of this magnitude, it takes partnerships and we are grateful to Canada for their collaboration, and to GSK for partnering with us to develop a safe and effective vaccine."

Roger Connor, President of GSK Vaccines said:

"GSK is proud to be working in partnership with Sanofi to make this vaccine available as soon as possible in Canada. Both companies have significant R&D and manufacturing capability world-wide and are already working hard to scale up production. This announcement from the Government of Canada supports our ongoing efforts."

Both companies have vaccine manufacturing sites in Canada that are contributing to overall global COVID-19 vaccine development, and these plus their global industrial networks will play a pivotal role in the production of the COVID-19 vaccine doses for Canada - as agreed today.

The Companies initiated a Phase 1/ 2 study on 3(rd) September and anticipate first results in early December 2020, to support the initiation of a Phase 3 study before the end of the year. If these data are sufficient for licensure application, it is planned to request regulatory approval in the first half of 2021 . In parallel, Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant with the target of producing up to one billion doses in total per year globally .

Sanofi and GSK are committed to making the COVID-19 vaccine available globally

On 18(th) September Sanofi and GSK signed a final agreement with the European Commission to supply European countries with up to 300 million doses from their European industrial networks.

In July 2020, Sanofi and GSK announced a collaborative effort with the U.S. government to supply up to 100 million doses of their adjuvanted COVID-19 recombinant vaccine. The U.S. government has a further option to discuss the purchase of up to an additional 500 million doses longer term. Both Companies also agreed with the UK government to supply up to 60 million doses of recombinant protein-based COVID-19 vaccine.

The partners plan to supply a significant portion of total worldwide available supply to COVAX, the vaccines pillar of the ACT-Accelerator (Access to COVID -- 19 Tools), a global collaboration of leaders of governments, global health organizations, businesses and philanthropies to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines.

GSK commitment to tackling COVID-19

GSK is collaborating with companies and research groups across the world working on promising COVID-19 vaccine candidates through the use of our pandemic adjuvant technology. The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protecting more people. GSK does not expect to profit from COVID-19 vaccines during the pandemic phase, and will invest any short-term profit in coronavirus related research and long-term pandemic preparedness, either through GSK internal investments or with external partners.

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us .

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

 
 GSK enquiries: 
 Media enquiries:   Simon Steel        +44 (0) 20 8047   (London) 
                                        5502 
                    Simon Moore        +44 (0) 20 8047   (London) 
                                        5502 
                    Kristen Neese      +1 804 217 8147   (Philadelphia) 
                    Kathleen Quinn     +1 202 603 5003   (Washington 
                                                          DC) 
 
 Analyst/Investor   Sarah Elton-Farr   +44 (0) 20 8047   (London) 
  enquiries:                            5194 
                    Sonya Ghobrial     +44 (0) 7392      (Consumer) 
                                        784784 
                    Danielle Smith     +44 (0) 20 8047   (London) 
                                        0932 
                    James Dodwell      +44 (0) 20 8047   (London) 
                                        2406 
                    Jeff McLaughlin    +1 215 751 7002   (Philadelphia) 
                    Frannie DeFranco   +1 215 751 4855   (Philadelphia) 
 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk Factors" in the company's Annual Report on Form 20-F for 2019 and as set out in GSK's Principal risks and uncertainties" section of the Q2 Results and any impacts of the COVID-19 pandemic .

.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFLFFRADIFFII

(END) Dow Jones Newswires

September 22, 2020 12:42 ET (16:42 GMT)

1 Year Glaxosmithkline Chart

1 Year Glaxosmithkline Chart

1 Month Glaxosmithkline Chart

1 Month Glaxosmithkline Chart
ADVFN Advertorial
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20201029 07:10:21